CA2606282C — Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity
Assigned to Shionogi and Co Ltd · Expires 2016-04-26 · 10y expired
What this patent protects
Novel compounds of formula (I) shown below are provided, having anti-HIV activity, particularly HIV integrase inhibitory activity, as well as processes for their preparation and intermediates used therein, for potential use as anti-HIV drugs. (see formula I) (wherein Z1 is NR4; R…
USPTO Abstract
Novel compounds of formula (I) shown below are provided, having anti-HIV activity, particularly HIV integrase inhibitory activity, as well as processes for their preparation and intermediates used therein, for potential use as anti-HIV drugs. (see formula I) (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.